IP Library Granted Patent US 8,617,139
Granted Patent B2
US 8,617,139 · App. 12/492,051 · Granted Dec 31, 2013

Ocular implant with shape change capabilities

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,617,139
App. No.
12/492,051
Granted
Dec 31, 2013
Kind
B2
Abstract

Disclosed are devices, methods and systems for treatment of eye disease such as glaucoma. Implants are described herein that enhance aqueous flow through the normal outflow system of the eye with minimal to no complications. The implant can be reversibly deformed to a first shape, such as a generally linear shape conducive to insertion. Upon insertion, the implant can deform to a second shape, such as a generally non-linear shape conducive to retention within the eye. The shape also improves fluid flow from the anterior chamber and prevents or reduces clogging.

Claims (16)

1. An ocular implant, comprising:

an elongate member having a flow pathway, at least one inflow port communicating with the flow pathway, and an outflow port communicating with the flow pathway, wherein the elongate member includes a first distal portion including a spring-loaded braided structure configured to form a first length and a first outer diameter when in tension and form a second length and a second outer diameter upon release of tension, wherein the first length is longer than the second length and the first outer diameter is smaller than the second outer diameter, the braided structure including a distal end secured by a solid bullet-nose structure, and a second portion formed at least partially of a non-braided structure, wherein the entire second portion is positioned proximal of the first portion along a longitudinal axis of the elongate member, the elongate member is configured to be implanted through a self-sealing corneal incision and positioned in the eye such that the inflow port communicates with the anterior chamber and the outflow port communicates with the suprachoroidal space.

2. An implant as in claim 1 , wherein the first portion is adapted to transition from the first length and the first outer diameter to the second length and the second outer diameter while the second portion remains unchanged in shape.

3. An implant as in claim 1 , wherein the second portion is overlayed with a braided structure.

4. An implant as in claim 1 , wherein the elongate member includes a third portion formed of a non-braided structure.

5. An implant as in claim 4 , wherein the first portion is positioned between the second and third portions.

6. An implant as in claim 1 , wherein the flow pathway is an internal lumen that extends through at least one of the first and second portions.

7. A system for treating an ocular disorder in a patient, comprising:

an elongate member having a flow pathway, at least one inflow port communicating with the flow pathway, and an outflow port communicating with the flow pathway, wherein the elongate member includes a first distal portion including a spring-loaded braided structure configured to form a first length and a first outer diameter when in tension and form a second length and a second outer diameter upon release of tension, wherein the first length is longer than the second length and the first outer diameter is smaller than the second outer diameter, the braided structure including a distal end secured by a solid bullet-nose structure, and a second portion formed at least partially of a non-braided structure, wherein the entire second portion is positioned proximal of the first portion along a longitudinal axis of the elongate member, wherein the elongate member is configured to be implanted through a self-sealing corneal incision and positioned in the eye such that the inflow port communicates with the anterior chamber and the outflow port communicates with the suprachoroidal space; and

a delivery device having a delivery component that removably attaches to the elongate member, wherein the delivery component is configured to secure the elongate member in tension during implantation of the elongate member.

8. A system as in claim 7 , wherein the delivery component comprises a delivery wire and a sheath, wherein the delivery wire can exert a distally-directed force against a distal portion of the elongate member while the sheath holds a proximal portion of the elongate member to maintain the elongate member in tension.

9. A system as in claim 7 , wherein the delivery wire has a sharpened distal tip.

10. A system as in claim 7 , wherein the delivery component has a sharpened distal tip.

11. A system as in claim 7 , wherein the delivery component has a blunt distal tip.

12. A system as in claim 7 , wherein at least a portion of the delivery component inserts into an internal lumen of the elongate member.

13. A system as in claim 7 , wherein at least a portion of the delivery component fits over the elongate member.

Assignments (3)
CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019 Recorded Dec 10, 2019
From: NOVARTIS AG
To: ALCON INC.
Reel/Frame 051454/0788 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2016
From: TRANSCEND MEDICAL, INC.
To: NOVARTIS AG
Reel/Frame 038967/0487 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2010
From: SILVESTRINI, THOMAS A.; JOHN, STEVEN; GARCIA, JOSE; LILLY, RICHARD S.
To: TRANSCEND MEDICAL, INC.
Reel/Frame 023923/0326 →